Related Experiment Video
Updated: Apr 9, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of
1Spine Tumor Center, Changzheng Hospital, Naval Medical University, 415 Feng Yang Road, Shanghai 200003, People's Republic of China.
Abstract:
Osteosarcoma (OS) is a lethal malignant orthotopic bone tumor that primarily affects children and adolescents. Biomimetic nanocarriers have attracted wide attention as a new strategy for delivering chemotherapy agents to the OS. However, challenges such as rapid clearance and limited targeting hinder the effectiveness of OS chemotherapy. In this study, we designed reactive oxygen species (ROS)-responsive nanoparticles (NPs) coated with an interleukin (IL)11-engineered macrophage membrane (MM). The camouflage by MMs prevents clearance of IL-11-engineered MM-coated NPs loaded with doxorubicin (IL-11/MM@NPs/Dox) by the immune system. Moreover, the macrophage membrane combined with surface-expressed IL-11 not only directed IL-11/MM@NPs/Dox to OS tissues but also selectively identified IL-11 receptor alpha (IL-11Rα)-enriched OS cells. Within these cells, elevated levels of ROS triggered the controlled release of Dox from the ROS-responsive NPs. The synergistic modification of targeted ligand conjugation and cell membrane coating on the ROS-responsive NPs enhanced drug availability and reduced toxic side effects, thereby boosting the efficacy of OS chemotherapy. In summary, our findings suggest that IL-11/MM@NPs/Dox represents a promising approach to improving OS chemotherapy efficacy while ensuring excellent biocompatibility.
Insights
Engineered nanoparticles coated with macrophage membranes target osteosarcoma (OS) cells. These nanoparticles release chemotherapy drugs in response to reactive oxygen species (ROS), improving OS treatment efficacy and biocompatibility.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Osteosarcoma (OS) is a deadly bone cancer primarily affecting young individuals.
- Current chemotherapy faces challenges like rapid clearance and poor targeting.
- Biomimetic nanocarriers offer a novel strategy for OS drug delivery.
Purpose of the Study:
- To design novel ROS-responsive nanoparticles (NPs) for enhanced osteosarcoma chemotherapy.
- To improve nanocarrier targeting and reduce systemic toxicity.
- To investigate the efficacy of IL-11-engineered macrophage membrane-coated NPs (IL-11/MM@NPs/Dox).
Main Methods:
- Development of ROS-responsive NPs loaded with doxorubicin (Dox).
- Coating NPs with interleukin-11 (IL-11)-engineered macrophage membranes (MM).
- Evaluation of immune system evasion, OS tissue targeting, and selective OS cell uptake.
Main Results:
- MM coating prevented immune clearance and directed NPs to OS tissues.
- IL-11 facilitated selective targeting of IL-11 receptor alpha (IL-11Rα)-enriched OS cells.
- Elevated ROS within OS cells triggered controlled Dox release, enhancing efficacy and reducing side effects.
Conclusions:
- IL-11/MM@NPs/Dox demonstrates improved drug delivery and biocompatibility for OS chemotherapy.
- This approach offers a promising strategy to boost OS treatment outcomes.
- The synergistic design enhances drug availability and minimizes toxic side effects.
